ELAN:NYE-Elanco Animal Health (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 13.41

Change

-0.23 (-1.69)%

Market Cap

USD 7.75B

Volume

4.15M

Analyst Target

USD 26.43
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-17 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

-0.46 (-0.29%)

USD 66.94B
TAK Takeda Pharmaceutical Co Ltd A..

-0.09 (-0.68%)

USD 41.54B
HLN Haleon plc

+0.06 (+0.71%)

USD 37.53B
TEVA Teva Pharma Industries Ltd ADR

-0.05 (-0.35%)

USD 15.97B
RDY Dr. Reddy’s Laboratories Ltd..

-0.95 (-1.28%)

USD 11.85B
CTLT Catalent Inc

-0.45 (-0.80%)

USD 10.04B
PRGO Perrigo Company PLC

-0.15 (-0.46%)

USD 4.26B
PBH Prestige Brand Holdings Inc

+0.02 (+0.03%)

USD 3.43B
EVT Eaton Vance Tax Advantaged Div..

-0.21 (-0.92%)

USD 3.26B
BHC Bausch Health Companies Inc

-0.12 (-1.35%)

USD 3.26B

ETFs Containing ELAN

PETZ:LSE 11.16 % 0.00 %

N/A

N/A
KATZ:XETRA 9.20 % 0.00 %

N/A

N/A
PETZ:SW 9.20 % 0.00 %

N/A

N/A
DFE:SW WisdomTree Europe SmallCa.. 1.15 % 0.00 %

N/A

N/A
DFEA:SW WisdomTree Europe SmallCa.. 1.15 % 0.00 %

N/A

USD 0.03B
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

+0.32 (+0%)

USD 0.69B
DFE:LSE WisdomTree Europe SmallCa.. 0.00 % 0.00 %

-10.10 (0%)

USD 0.06B
DFEA:LSE WisdomTree Europe SmallCa.. 0.00 % 0.00 %

-0.12 (0%)

USD 0.03B
DFEE:LSE WisdomTree Issuer ICAV - .. 0.00 % 0.00 %

-0.11 (0%)

USD 0.06B
DFEP:LSE WisdomTree Europe SmallCa.. 0.00 % 0.00 %

-3.30 (0%)

USD 0.03B
XGLF:LSE db x-trackers MSCI GCC Se.. 0.00 % 0.00 %

+0.04 (+0%)

USD 0.02B
WTD7:F WisdomTree Issuer ICAV - .. 0.00 % 0.00 %

+0.22 (+0%)

USD 0.06B
WTES:F WisdomTree Issuer ICAV - .. 0.00 % 0.00 %

+0.21 (+0%)

USD 0.06B
XGLF:F db x-trackers MSCI GCC Se.. 0.00 % 0.00 %

-0.04 (0%)

USD 0.02B
WTD7:XETRA WisdomTree Issuer ICAV - .. 0.00 % 0.00 %

-0.11 (0%)

USD 0.06B
WTES:XETRA WisdomTree Europe SmallCa.. 0.00 % 0.00 %

-0.11 (0%)

USD 0.06B
XGLF:XETRA db x-trackers MSCI GCC Se.. 0.00 % 0.00 %

+0.09 (+0%)

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.00% 41% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.00% 41% F 16% F
Trailing 12 Months  
Capital Gain 41.75% 82% B 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.75% 82% B 91% A-
Trailing 5 Years  
Capital Gain -56.89% 43% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -56.89% 43% F 8% B-
Average Annual (5 Year Horizon)  
Capital Gain -11.49% 31% F 8% B-
Dividend Return -11.49% 31% F 7% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 37.73% 44% F 28% F
Risk Adjusted Return -30.46% 31% F 12% F
Market Capitalization 7.75B 65% D 82% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector